Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chemins

This article was originally published in The Tan Sheet

Executive Summary

July sentencing scheduled for dietary supplement manufacturer and its founder and president, who pleaded guilty Jan. 6 to charges of conspiring to hide use of ephedrine hydrochloride and caffeine anhydrous from the FDA. In exchange for the plea, the U.S. Attorney agrees to dismiss the remaining counts of the indictment, including product misbranding; making false statements; aiding and abetting; and obstructing FDA's investigation into the firm's alleged use of pharmaceutical-grade ephedrine and caffeine in supplements. Chemins and exec James Cameron originally entered not guilty pleas in Denver federal court Nov. 9 (1"The Tan Sheet" Nov. 15, 1999, In Brief)
Advertisement

Related Content

Chemins
Chemins

Topics

Advertisement
UsernamePublicRestriction

Register

PS090950

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel